{"id":162825,"date":"2020-01-06T06:10:04","date_gmt":"2020-01-06T11:10:04","guid":{"rendered":"https:\/\/www.countingpips.com\/?p=162825"},"modified":"2020-01-05T20:10:31","modified_gmt":"2020-01-06T01:10:31","slug":"biopharmas-phase-3-trial-results-in-migraine-robust-impressive","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex\/2020\/01\/biopharmas-phase-3-trial-results-in-migraine-robust-impressive\/","title":{"rendered":"Biopharma’s Phase 3 Trial Results in Migraine ‘Robust,’ ‘Impressive’"},"content":{"rendered":"
January 6, 2020<\/div>
\r\n<\/div><\/div>

By The Life Science Report<\/b><\/p>\n

Source: Streetwise Reports<\/em> \u00a0\u00a001\/03\/2020<\/a><\/b><\/p>\n

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report.<\/strong><\/p>\n

In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ)<\/a> to $165 per share from $135 following “robust” results from the biopharma’s Phase 3 AXS-07 MOMENTUM trial in migraines in difficult to treat patients. Axsome’s current share price, in comparison, is about $101.31.<\/p>\n

These Phase 3 data increase the likelihood that the U.S. Food and Drug Administration (FDA) approves AXS-07, Kaplan commented. Axsome intends to file a new drug application with the FDA for AXS-07 in H2\/20. Before that date, in Q1\/20, topline results will be available from the AXS-07 INTERCEPT Phase 3 trial in migraines.<\/p>\n

The analyst reviewed the study’s outcome. The topline efficacy results were “impressive,” he added, demonstrating “rapid, durable and highly statistically significant improvements in primary and secondary endpoints evaluated.” The fact that Axsome achieved these results in patients with a history of inadequate response to prior acute treatments is “even more remarkable.”<\/p>

\r\n
\r\n

Free Reports:<\/p><\/div>\r\n

\r\n

<\/a>\r\n\t Get Our Free Metatrader 4 Indicators<\/u><\/b><\/a> - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter<\/p>

\r\n
\r\n
\r\n

<\/a>\r\n\t Get our Weekly Commitment of Traders Reports<\/u><\/b><\/a> - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.<\/p>

\r\n<\/div>\r\n

\r\n
<\/div>\n

The two primary endpoints were freedom from pain and freedom from the most bothersome symptom, either photophobia, phonophobia or nausea, both at two hours post treatment. AXS-07 resulted in a 19.9% rate of pain relief at two hours versus 6.7% for placebo and a 36.9% rate of relief from the most bothersome symptom compared to 24.4% with placebo.<\/p>\n

The secondary endpoints were superiority of AXS-07 over the individual components, rizatriptan and MoSEIC meloxicam, based on sustained pain relief two to 24 hours after dosing. “Overall, AXS-07 showed clear superiority over rizatriptan as it demonstrated statistically significant results for one-hour pain relief, two- to 24-hour sustained pain relief, two- to 48-hour pain relief, two- to 24-hour sustained pain freedom, two- to 48-hour sustained pain freedom, patient global impression of change, functional improvement at 24 hours and use of rescue medications,” explained Kaplan.<\/p>\n

He noted further that AXS-07 proved to be safe and was well tolerated. The most frequently experienced adverse events were nausea, dizziness and somnolence, which occurred as often or less often as that with a placebo.<\/p>\n

Kaplan concluded that “AXS-07’s multimechanistic modes of action represent an attractive novel treatment option in both the frontline and refractory migraine treatment settings.”<\/p>\n

Sign up for our FREE newsletter at: www.streetwisereports.com\/get-news<\/a><\/p>\n

Disclosure: <\/b>
\n1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
\n2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here<\/a> for important disclosures about sponsor fees.
\n3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
\n4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer<\/a>. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
\n5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and\/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.<\/p>\n

Disclosures from Ladenburg Thalmann, Axsome Therapeutics Inc., December 30, 2019<\/b><\/i><\/p>\n

ANALYST CERTIFICATION: <\/b>I, Matthew L. Kaplan, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:<\/p>\n

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm\u0092s total revenues, a portion of which is generated by investment banking activities.<\/p>\n

COMPANY SPECIFIC DISCLOSURES:<\/b><\/p>\n

Ladenburg Thalmann & Co. Inc. makes a market in Axsome Therapeutics, Inc.
\nLadenburg Thalmann & Co. Inc. has managed or co-managed a public offering for Axsome Therapeutics, Inc. within the past 12 months.
\nLadenburg Thalmann & Co. Inc. expects to receive compensation for investment banking and\/or advisory services from Axsome Therapeutics, Inc. within the next 3 months.
\nLadenburg Thalmann & Co. Inc. intends to seek compensation for investment banking and\/or advisory services from Axsome Therapeutics, Inc. within the next 3 months.
\nLadenburg Thalmann & Co. Inc received compensation for investment banking services from Axsome Therapeutics, Inc. within the past 12
\nmonths.
\nLadenburg Thalmann & Co. Inc had an investment banking relationship with Axsome Therapeutics, Inc. within the last 12 months.
\nLadenburg Thalmann & Co Inc. acted in an advisory capacity for Axsome Therapeutics, Inc. in the last 12 months.
\nMatthew L. Kaplan, or a member of their household, has a financial interest in the securities of Axsome Therapeutics, Inc. (AXSM) in the form of (long position in common).
\nThe research analyst principally responsible for the preparation of this research report, or a member of their household, has a financial interest in the securities of Axsome Therapeutics, Inc. in the form of a long position in common stock.<\/p>\n

<\/p>\n

( Companies Mentioned: AXSM:NASDAQ,
\n)<\/p>\n

<\/a> <\/a><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

By The Life Science Report Source: Streetwise Reports \u00a0\u00a001\/03\/2020 These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $165 per share from $135 following […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-162825","post","type-post","status-publish","format-standard","hentry","no-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts\/162825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/comments?post=162825"}],"version-history":[{"count":2,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts\/162825\/revisions"}],"predecessor-version":[{"id":162850,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/posts\/162825\/revisions\/162850"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/media?parent=162825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/categories?post=162825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/forex\/wp-json\/wp\/v2\/tags?post=162825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}